328 related articles for article (PubMed ID: 16539696)
21. Mutational analysis of the BRCA1-interacting genes ZNF350/ZBRK1 and BRIP1/BACH1 among BRCA1 and BRCA2-negative probands from breast-ovarian cancer families and among early-onset breast cancer cases and reference individuals.
Rutter JL; Smith AM; Dávila MR; Sigurdson AJ; Giusti RM; Pineda MA; Doody MM; Tucker MA; Greene MH; Zhang J; Struewing JP
Hum Mutat; 2003 Aug; 22(2):121-8. PubMed ID: 12872252
[TBL] [Abstract][Full Text] [Related]
22. Screening for BRCA1 and BRCA2 mutations in Eastern Finnish breast/ovarian cancer families.
Hartikainen JM; Kataja V; Pirskanen M; Arffman A; Ristonmaa U; Vahteristo P; Ryynänen M; Heinonen S; Kosma VM; Mannermaa A
Clin Genet; 2007 Oct; 72(4):311-20. PubMed ID: 17850627
[TBL] [Abstract][Full Text] [Related]
23. A targeted analysis identifies a high frequency of BRCA1 and BRCA2 mutation carriers in women with ovarian cancer from a founder population.
Belanger MH; Dolman L; Arcand SL; Shen Z; Chong G; Mes-Masson AM; Provencher D; Tonin PN
J Ovarian Res; 2015 Mar; 8():1. PubMed ID: 25884701
[TBL] [Abstract][Full Text] [Related]
24. BRCA1 and BRCA2 mutation prevalence and clinical characteristics of a population-based series of ovarian cancer cases from Denmark.
Soegaard M; Kjaer SK; Cox M; Wozniak E; Høgdall E; Høgdall C; Blaakaer J; Jacobs IJ; Gayther SA; Ramus SJ
Clin Cancer Res; 2008 Jun; 14(12):3761-7. PubMed ID: 18559594
[TBL] [Abstract][Full Text] [Related]
25. Haplotype analysis in Icelandic and Finnish BRCA2 999del5 breast cancer families.
Barkardottir RB; Sarantaus L; Arason A; Vehmanen P; Bendahl PO; Kainu T; Syrjäkoski K; Krahe R; Huusko P; Pyrhönen S; Holli K; Kallioniemi OP; Egilsson V; Kere J; Nevanlinna H
Eur J Hum Genet; 2001 Oct; 9(10):773-9. PubMed ID: 11781689
[TBL] [Abstract][Full Text] [Related]
26. High frequency and allele-specific differences of BRCA1 founder mutations in breast cancer and ovarian cancer patients from Belarus.
Bogdanova NV; Antonenkova NN; Rogov YI; Karstens JH; Hillemanns P; Dörk T
Clin Genet; 2010 Oct; 78(4):364-72. PubMed ID: 20569256
[TBL] [Abstract][Full Text] [Related]
27. Multiple founder effects and geographical clustering of BRCA1 and BRCA2 families in Finland.
Sarantaus L; Huusko P; Eerola H; Launonen V; Vehmanen P; Rapakko K; Gillanders E; Syrjäkoski K; Kainu T; Vahteristo P; Krahe R; Pääkkönen K; Hartikainen J; Blomqvist C; Löppönen T; Holli K; Ryynänen M; Bützow R; Borg A; Wasteson Arver B; Holmberg E; Mannermaa A; Kere J; Kallioniemi OP; Winqvist R; Nevanlinna H
Eur J Hum Genet; 2000 Oct; 8(10):757-63. PubMed ID: 11039575
[TBL] [Abstract][Full Text] [Related]
28. Haplotype analysis of two recurrent genomic rearrangements in the BRCA1 gene suggests they are founder mutations for the Greek population.
Pertesi M; Konstantopoulou I; Yannoukakos D
Clin Genet; 2011 Oct; 80(4):375-82. PubMed ID: 20840220
[TBL] [Abstract][Full Text] [Related]
29. Parity and the risk of breast and ovarian cancer in BRCA1 and BRCA2 mutation carriers.
Milne RL; Osorio A; Ramón y Cajal T; Baiget M; Lasa A; Diaz-Rubio E; de la Hoya M; Caldés T; Teulé A; Lázaro C; Blanco I; Balmaña J; Sánchez-Ollé G; Vega A; Blanco A; Chirivella I; Esteban Cardeñosa E; Durán M; Velasco E; Martínez de Dueñas E; Tejada MI; Miramar MD; Calvo MT; Guillén-Ponce C; Salazar R; San Román C; Urioste M; Benítez J
Breast Cancer Res Treat; 2010 Jan; 119(1):221-32. PubMed ID: 19370414
[TBL] [Abstract][Full Text] [Related]
30. Founder BRCA1 and BRCA2 mutations in French Canadian breast and ovarian cancer families.
Tonin PN; Mes-Masson AM; Futreal PA; Morgan K; Mahon M; Foulkes WD; Cole DE; Provencher D; Ghadirian P; Narod SA
Am J Hum Genet; 1998 Nov; 63(5):1341-51. PubMed ID: 9792861
[TBL] [Abstract][Full Text] [Related]
31. Application of BRCA1 and BRCA2 mutation carrier prediction models in breast and/or ovarian cancer families of French Canadian descent.
Oros KK; Ghadirian P; Maugard CM; Perret C; Paredes Y; Mes-Masson AM; Foulkes WD; Provencher D; Tonin PN
Clin Genet; 2006 Oct; 70(4):320-9. PubMed ID: 16965326
[TBL] [Abstract][Full Text] [Related]
32. Molecular and genealogical characterization of the R1443X BRCA1 mutation in high-risk French-Canadian breast/ovarian cancer families.
Vézina H; Durocher F; Dumont M; Houde L; Szabo C; Tranchant M; Chiquette J; Plante M; Laframboise R; Lépine J; Nevanlinna H; Stoppa-Lyonnet D; Goldgar D; Bridge P; Simard J
Hum Genet; 2005 Jul; 117(2-3):119-32. PubMed ID: 15883839
[TBL] [Abstract][Full Text] [Related]
33. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada.
Risch HA; McLaughlin JR; Cole DE; Rosen B; Bradley L; Fan I; Tang J; Li S; Zhang S; Shaw PA; Narod SA
J Natl Cancer Inst; 2006 Dec; 98(23):1694-706. PubMed ID: 17148771
[TBL] [Abstract][Full Text] [Related]
34. Three novel BRCA1/BRCA2 mutations in breast/ovarian cancer families in Croatia.
Levanat S; Musani V; Cvok ML; Susac I; Sabol M; Ozretic P; Car D; Eljuga D; Eljuga L; Eljuga D
Gene; 2012 May; 498(2):169-76. PubMed ID: 22366370
[TBL] [Abstract][Full Text] [Related]
35. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2.
Roa BB; Boyd AA; Volcik K; Richards CS
Nat Genet; 1996 Oct; 14(2):185-7. PubMed ID: 8841191
[TBL] [Abstract][Full Text] [Related]
36. High proportion of recurrent germline mutations in the BRCA1 gene in breast and ovarian cancer patients from the Prague area.
Pohlreich P; Zikan M; Stribrna J; Kleibl Z; Janatova M; Kotlas J; Zidovska J; Novotny J; Petruzelka L; Szabo C; Matous B
Breast Cancer Res; 2005; 7(5):R728-36. PubMed ID: 16168118
[TBL] [Abstract][Full Text] [Related]
37. Haplotype analysis of BRCA2 8765delAG mutation carriers in French Canadian and Yemenite Jewish hereditary breast cancer families.
Manning AP; Abelovich D; Ghadirian P; Lambert JA; Frappier D; Provencher D; Robidoux A; Peretz T; Narod SA; Mes-Masson AM; Foulkes WD; Wang T; Morgan K; Fujiwara TM; Tonin PN
Hum Hered; 2001; 52(2):116-20. PubMed ID: 11512557
[TBL] [Abstract][Full Text] [Related]
38. Founder mutations account for the majority of BRCA1-attributable hereditary breast/ovarian cancer cases in a population from Tuscany, Central Italy.
Papi L; Putignano AL; Congregati C; Zanna I; Sera F; Morrone D; Falchetti M; Turco MR; Ottini L; Palli D; Genuardi M
Breast Cancer Res Treat; 2009 Oct; 117(3):497-504. PubMed ID: 18821011
[TBL] [Abstract][Full Text] [Related]
39. Appendectomy and cancer risk in Jewish BRCA1 and BRCA2 mutation carriers.
Bernholtz S; Jakobson-Setton A; Korach J; Ben Baruch G; Laitman Y; Friedman E
Breast Cancer Res Treat; 2012 Feb; 131(3):981-5. PubMed ID: 21984204
[TBL] [Abstract][Full Text] [Related]
40. The BRCA2 c.9004G>A (E2002K) [corrected] variant is likely pathogenic and recurs in breast and/or ovarian cancer families of French Canadian descent.
Cote S; Arcand SL; Royer R; Nolet S; Mes-Masson AM; Ghadirian P; Foulkes WD; Tischkowitz M; Narod SA; Provencher D; Tonin PN
Breast Cancer Res Treat; 2012 Jan; 131(1):333-40. PubMed ID: 21947752
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
